Pharvaris (PHVS) Phase 3 Shows Deucrictibant IR Met All Endpoints in HAE
Pharvaris reported that its Phase 3 trial, RAPIDe-3, met all primary and secondary endpoints for deucrictibant IR in treating HAE attacks. The company noted rapid symptom control and no safety concerns. An NDA is under FDA review with a PDUFA target date of April 23, 2027.
How this was made
The 30-second read
Why it matters
Meeting all endpoints with no safety signals reduces clinical risk and increases perceived probability of a favorable FDA outcome, while the stated PDUFA target date provides a concrete catalyst for positioning.
Market read
Traders can update approval-probability assumptions and risk management into the FDA review window based on the reported Phase 3 endpoint success and the PDUFA target date.
What to watch
The article does not quantify effect sizes, durability, or subgroup performance, which can matter for FDA label negotiations and commercial differentiation despite endpoint “met” language.
Background
The piece frames RAPIDe-3 as late-stage confirmation for Pharvaris’ oral on-demand deucrictibant program in hereditary angioedema (HAE), following earlier Phase 2/3 data.
Ticker impact
Pharvaris reports RAPIDe-3 Phase 3 oral deucrictibant in HAE met primary and all 11 secondary endpoints, with no safety signals and an FDA NDA review/PDUFA date.
Likely upward pressure as traders price higher probability of regulatory progress ahead of the Apr. 23, 2027 PDUFA target.
The article discloses Phase 3 endpoint success plus a concrete regulatory timeline (PDUFA target), which typically increases perceived approval probability for biotech assets.
Market effects
Reinforces confidence in oral on-demand therapies for hereditary angioedema, potentially lifting sentiment across rare-disease and HAE peers with similar mechanisms.
Limited direct regional spillover; most impact is biotech-specific sentiment rather than broad macro.
FDA review milestone (PDUFA target) is US-centric, but positive Phase 3 data can influence global regulatory expectations (FDA/EMA) for the class.
Counterpoint
Endpoint success may already be partially anticipated by prior Phase 2/3 signals, so near-term trading could fade if investors focus on remaining regulatory risks like label scope or manufacturing/CMC questions not addressed here.
Key entities
- companyPharvaris
Subject of the article, reporting RAPIDe-3 Phase 3 success for oral deucrictibant in HAE and an FDA NDA review timeline.
- clinical_trialRAPIDe-3
Phase 3 study of oral deucrictibant IR in HAE attacks, reported as meeting primary and all secondary endpoints.
- regulatorFDA
NDA is under review with a stated PDUFA target date of Apr. 23, 2027.
